ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹47.05-0.59%
07 Jul 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth.
Market Cap Distribution
Large Cap (36.7%)
Mid Cap (23.2%)
Small Cap (40.0%)
Historical Asset Allocation
| Asset | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 | 31 Dec 2025 |
|---|---|---|---|---|---|---|
| Equity | 99.82% | 96.76% | 97.62% | 97.98% | 97.60% | 97.87% |
| Debt | 0.00% | 0.00% | 0.03% | 0.03% | 0.03% | 0.00% |
| Others (incl. cash) | 0.18% | 3.24% | 2.35% | 1.99% | 2.37% | 2.13% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
38
P/E Ratio
35.24
P/B Ratio
4.35
Top Holding %
12.09%
Top 5 Holdings %
40.33%
Top 10 Holdings %
60.73%
AUM
₹6,454 Cr
Expense Ratio
1.33%
Since Inception
21.39%
Max Drawdown
-0.21%
Alpha
2.11%
Sharpe Ratio
1.17
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 43,38,091 | 780.51 | 12.09% | 0.33%↑ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 38,11,568 | 496.84 | 7.70% | 1.76%↑ |
| Cipla Ltd. | Healthcare | 34,30,942 | 480.68 | 7.45% | -0.70%↓ |
| Mankind Pharma Ltd. | Healthcare | 19,09,575 | 453.64 | 7.03% | -0.55%↓ |
| Divis Laboratories Ltd. | Healthcare | 5,86,962 | 391.33 | 6.06% | -0.00%↓ |
| Biocon Ltd. | Healthcare | 70,98,250 | 304.27 | 4.71% | -1.10%↓ |
| Cohance Lifesciences Ltd. | Healthcare | 65,38,941 | 282.16 | 4.37% | -0.06%↓ |
| Alkem Laboratories Ltd. | Healthcare | 4,79,158 | 263.44 | 4.08% | 0.84%↑ |
| Medplus Health Services Ltd. | Healthcare | 27,82,070 | 249.05 | 3.86% | 0.49%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 22,50,000 | 217.15 | 3.36% | - |
| Lupin Ltd. | Healthcare | 8,69,954 | 197.28 | 3.06% | -0.75%↓ |
| Syngene International Ltd. | Healthcare | 43,60,323 | 192.73 | 2.99% | -0.11%↓ |
| Thyrocare Technologies Ltd. | Healthcare | 30,52,801 | 154.56 | 2.40% | 0.52%↑ |
| Abbott India Ltd. | Healthcare | 51,371 | 137.96 | 2.14% | 0.25%↑ |
| Akums Drugs And Pharmaceuticals Ltd. | Healthcare | 24,67,084 | 129.4 | 2.01% | -0.02%↓ |
| Pfizer Ltd. | Healthcare | 2,77,423 | 127.57 | 1.98% | 0.02%↑ |
| JB Chemicals & Pharmaceuticals Ltd. | Healthcare | 5,78,725 | 125.43 | 1.94% | 0.17%↑ |
| Aurobindo Pharma Ltd. | Healthcare | 8,70,394 | 124.15 | 1.92% | -0.01%↓ |
| Alivus Life Sciences Ltd | Healthcare | 10,80,414 | 114.04 | 1.77% | 0.04%↑ |
| Alembic Pharmaceuticals Ltd. | Healthcare | 15,41,322 | 113.46 | 1.76% | 0.01%↑ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 | 31 Dec 2025 |
|---|---|---|---|---|---|---|
| Healthcare | 97.25% | 94.36% | 95.42% | 95.50% | 95.07% | 95.07% |
| Services | 1.38% | 1.25% | 1.14% | 1.31% | 1.44% | 1.71% |
| Chemicals | 1.19% | 1.15% | 1.06% | 1.17% | 1.09% | 1.09% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
38.2 / 100
Weighted average Value score is 38.2. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
74.5 / 100
Weighted average Price Momentum score is 74.5. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
83.5 / 100
Weighted average Quality score is 83.5. This indicates that portfolio has high quality using composite of quality measures.
QVM score
77.4 / 100
Weighted average QVM score is 77.4. This indicates that portfolio has high QVM score and hence could be considered for investment.
Red Flags
Frequently Asked Questions
What are the top holdings of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The top holdings of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth sorted by portfolio weight are listed in the Top Portfolio Holdings section of the Holdings tab.
How many stocks does ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth hold in its portfolio?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth holds 38 securities in its portfolio. The top 5 holdings account for 40.33% of the portfolio and the top 10 for 60.73%.
What is the sector allocation of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The sector allocation of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is in the Sector Allocation section, showing each industry's weight in the portfolio.
What is the equity and debt allocation of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
As of 31 May 2026, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth has 99.82% in equity, 0.00% in debt and 0.18% in cash/others. This asset mix determines the fund's overall risk-return profile.
What is the market cap allocation of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth's equity portfolio — Large Cap: 36.74%, Mid Cap: 23.23%, Small Cap: 40.03%. Market cap allocation determines the fund's risk profile — large cap offers stability while mid and small cap offer higher growth potential with higher volatility.
Is ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth a concentrated or diversified fund?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth holds 38 securities, with the top 10 accounting for 60.73% of the portfolio and the top 5 for 40.33%. This is a moderately diversified fund balancing conviction positions with risk spread.
What is the credit quality of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The credit quality breakdown of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth's debt portfolio is in the Credit Rating section. For equity-oriented funds, this section may not be applicable.
How often does ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth change its portfolio?
The portfolio currently holds 38 securities with the top 10 accounting for 60.73% as of 31 May 2026. Portfolio turnover reflects how actively the fund manager trades. A high turnover increases transaction costs while a low turnover reflects a buy-and-hold approach. Historical asset allocation snapshots across multiple dates are in the Holdings Analysis section.
What is the PE ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth's portfolio?
The weighted average PE ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth's portfolio is 35.24 and the PB ratio is 4.35. These metrics reflect the overall valuation and interest rate sensitivity of the portfolio.
When is the latest portfolio disclosure for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The latest portfolio disclosure for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is as of 31 May 2026. Mutual funds and ETFs in India are required to disclose their full portfolio monthly, within 10 business days of month-end. You can switch between historical disclosure dates using the date selector in the Top Portfolio Holdings section.